5973-28-4

Basic information

• Product Name: 7-chloro-1-methyl-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione
• CAS NO: 5973-28-4
• Molecular Formula: C₁₀H₉ClN₂O₂
• Molecular Weight: 224.6437
• Mol File: 5973-28-4.mol

Chemical Properties

• Boiling Point: 611.4°C at 760 mmHg
• Flash Point: 323.5°C
• Density: 1.352g/cm³
• Vapor Pressure: 6.93E-15mmHg at 25°C
• Refractive Index: 1.579
• CAS DataBase Reference: 7-chloro-1-methyl-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 7-chloro-1-methyl-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione(5973-28-4)
• EPA Substance Registry System: 7-chloro-1-methyl-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione(5973-28-4)

Safety Data

• Hazardous Substances Data: 5973-28-4(Hazardous Substances Data)

Upstream product

• 54888-03-8 5-chloro-2-(aceturoylmethylamino)benzophenone 
• 72952-53-5 5-chloro-2-(methylamino)hippuric acid 
• 72952-48-8 N-acetyl-7-chloro-3,4-dihydro-1-methyl-1H-1,4-benzodiazepine-2,5-dione 
• 72952-52-4 potassium 5-chloro-2-(methylamino)hippurate 
• 10379-14-3 tetrazepam 
• 4743-17-3 5-Chloroisatoic anhydride 
• 14529-12-5 6-chloro-N-methylisatoic anhydride 
• 1022-13-5 5-chloro-2-(methylamino)benzophenone 
• 56-40-6 glycine 

Downstream Products

• 1059064-05-9 7-chloro-5-(4-hydroxyphenyl)-1-methyl-3-(4-(trifluoromethyl)benzyl)-1H-benzo[e][1,4]diazepin-2(3H)-one 
• 1059066-03-3 7-chloro-5-(4-(4-methoxybenzyloxy)phenyl)-1-methyl-3-(4-(trifluoromethyl)benzyl)-1H-benzo[e][1,4]diazepin-2(3H)-one 
• 1059066-02-2 7-chloro-5-(4-(4-methoxybenzyloxy)phenyl)-1-methyl-1H-benzo[e][1,4]diazepin-2(3H)-one 
• 1059063-99-8 7-chloro-3-(2-chlorobenzyl)-5-(4-hydroxyphenyl)-1-methyl-1H-benzo[e][1,4]diazepin-2(3H)-one 
• 1059065-60-9 7-chloro-3-(2-chlorobenzyl)-5-(4-methoxyphenyl)-1-methyl-1H-benzo[e][1,4]diazepin-2(3H)-one 
• 1059065-59-6 7-chloro-5-(4-methoxyphenyl)-1-methyl-3-(2-methylbenzyl)-1H-benzo[e][1,4]diazepin-2(3H)-one 
• 1059065-47-2 (E)-3-(2-bromobenzyl)-5,7-dichloro-1-methyl-1H-benzo[e][1,4]diazepin-2(3H)-one 
• 1059064-02-6 3-(2-bromobenzyl)-7-chloro-1-methyl-5-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)-1H-benzo[e][1,4]diazepin-2(3H)-one 
• 72952-51-3 N-{[(2-Benzoyl-4-chloro-phenyl)-methyl-carbamoyl]-methyl}-isobutyramide 

Relevant articles and documents

BENZODIAZEPINONE COMPOUNDS AND METHODS OF TREATMENT USING SAME

The invention provides 1,4-benzodiazepinone compounds, pharmaceutical compositions, and methods of treating autoimmune disorders, chronic inflammatory disorders, and hyperproliferative disorders. For example, the 1,4-benzodiazepinone compounds and pharmaceutical compositions are contemplated to be useful for treating rheumatoid arthritis, graft-versus-host disease, inflammatory bowel disease, and the like.

BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS

The present invention provides a family of benzodiazepinone compounds and pharmaceutical compositions thereof. The present invention also provides methods of treating certain skin conditions, e.g., atopic dermatitis, rosacea, or psoriasis, by administering a benzodiazepinone and methods of reducing the proliferation of keratinocyte cells by exposing such cells to a benzodiazepinone.

COMPOSITIONS AND METHODS RELATING TO NOVEL COMPOUNDS AND TARGETS THEREOF

The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine compounds, and structurally and functionally related compounds, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, hyperproliferation, vascular abnormalities, and the like.

Autoxidation of drugs: Prediction of degradation impurities from results of reaction with radical chain initiators

In the study of the degradation of drug substances by molecular oxygen, their specific reaction mechanisms must be taken into account. The rate- determining step is usually the reaction of the substrate with a radical chain initiator, which is often an unknown impurity. The reactivity and selectivity of autoxidation can be controlled better by using a radical chain initiator, such as AIBN, than by changing the temperature or the oxygen pressure. In this paper the products profiles of four pharmaceutical substances in a simple oxidation test with AIBN are compared with the results of long term natural stability tests or with already established stabilities.

Autoxidation of tetrazepam in tablets: Prediction of degradation impurities from the oxidative behavior in solution

The major route of degradation of tetrazepam (1) is oxidation to 7-chloro- 5-(3-keto-cyclohexen-1-yl)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one (3) via the stable 7-chloro-5-(3-hydroperoxy-cyclohexen-1-yl)-1,3-dihydro-1- methyl-2H-1,4 benzodiazepin-2-one (2). Minor degradation products are 7- chloro-5-(1,2-epoxycyclohexan-1-yl)-1,3-dihydro-1-methyl-2H-1,4- benzodiazepin-2-one (5) and 7-chloro-1,3-dihydro-1-methyl-2H-1,4- benzodiazepin-2,5-dione (4), resulting from cleavage of the C-C bond between the cyclohexene ring and the benzodiazepine ring. After 48 h, AIBN (2,2'- azobis[2-methyl-propanenitrile]) in acetonitrile at 40 °C produced qualitatively the same impurities as those observed in the stability study of tablets of 1. Other stress tests (thermal stress at 80 °C, heavy metal oxidation, hydrogen peroxide, acid-catalyzed oxidation) caused qualitatively different profiles of degradation.

New Synthesis of Diazepam

An efficient preparation of 7-chloro-1-methyl-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione from 5-chloro-N-methylisatoic anhydride and glycine has been devised, and from it, by the action of phenylmagnesium chloride on its N-acetyl-derivative followed by treatment with hydroxylamine and cleavage of the resulting desacetyl oxime with sodium bisulfite, diazepam has been synthesized.The overall yield is about 50percent from 5-chloroisatoic anhydride.